Loading stock data…
Stereotaxis, Inc. (STXS)
$1.73+0.05 (+2.98%)
Market ClosedLast close Jun 29
Stereotaxis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stereotaxis, Inc. in the Healthcare sector is trading at $1.73 with a market capitalization of $180M. Wall Street consensus targets $4.12 (4 analysts), implying a +138.4% move over the next 12 months. The stock is currently near its 52-week low of $1.59, remaining 24.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +138.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.29M↓ | $8.64M↑ | $7.46M↓ | $8.80M↑ | $7.47M |
| Gross Profit | $3.79M↓ | $4.33M↑ | $4.10M↓ | $4.58M↑ | $4.06M |
| Operating Income | -$5.98M↓ | -$5.65M↑ | -$6.56M↓ | -$3.98M↑ | -$5.93M |
| Net Income | -$5.86M↓ | -$5.53M↑ | -$6.46M↓ | -$3.83M↑ | -$5.82M |
Peer Comparison
JNJUNHPFE
Fundamentals
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$179.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-110.63%
Volume
Today's trading volume
497,750
Recent News
ISRG's Capital Placement Surge: Demand Strength or Upgrade Cycle Peak?
ISRG placed 431 da Vinci systems in Q1 2026, but rising trade-ins and leasing growth raise questions about whether demand is structural or upgrade-driven.
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
Analysts See 124.7% Upside In Stereotaxis (STXS); Find Out Why
Trading with an implied upside of 124.7% and an RSI of 39.6, Stereotaxis, Inc. (NYSEAMERICAN:STXS) has emerged as a notable oversold play in the AI sector. However, more recently, Piper Sandler lowered its price target on Stereotaxis, Inc. (NYSEAMERICAN:STXS) to $3.5 from $4.0 on May 13, 2026, while keeping an “Overweight” rating. The firm pointed […]
Stereotaxis Inc (STXS) Q1 2026 Earnings Call Highlights: Navigating Regulatory Wins and Revenue ...
Stereotaxis Inc (STXS) secures key regulatory approvals and launches innovative products amid revenue decline and production constraints.
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +25.00% and -30.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?